Download This listing of Pathology/Laboratory applications is being posted

Pathology/Laboratory CPT Code Change Applications
February 2017 CPT® Editorial Panel Meeting
Pathology/Laboratory CPT Code Change Applications that have been submitted for consideration by the CPT Editorial Panel at its February
2017 meeting are listed below. These applications will be included in the proposed Panel agenda that will be posted to the AMA website on
December 9, 2016. This listing includes the code application names, code(s) affected, and a description of the request. The Code numbers
and Request Descriptions detailed in this document are extracted from Code Applications submitted for discussion at this meeting. Until
such time as the CPT Editorial Panel acts on these requests, the following information is provided for informational purposes only, giving
interested individuals the information to help determine whether or not to attend the meeting and provide comment on a given topic(s).
This listing of Pathology/Laboratory applications is being posted ahead of the full February Panel meeting agenda in order to provide the
Molecular Pathology Advisory Group (MPAG) and the Pathology Coding Caucus (PCC) sufficient time to review comments from interested
stakeholders individuals who wish to comment prior to making their recommendations to the CPT Editorial Panel.
Codes that contain an ‘X’ (e.g., 1002X4, 234X2X, 0301XT) below are placeholder codes that are intended, through the first three digits, to give
readers an idea of the proposed placement in the code set of the potential code changes. These codes are not used for claims reporting and
will be removed and not retained when the final CPT Datafiles are distributed on August 31st of each year. To report the services for “X”
codes listed on this form, please refer to the actual codes as they appear in the CPT Datafiles publication distributed on August 31st of each
year.
Upon review of these applications, if the reviewer believes that they will need to provide comment on an issue, they should send a
request for a copy of the application and associated materials to Judy Connelly. This request for review of the agenda materials should
contain the identity of the interested party seeking such and a brief summary of the basis for the request (e.g., associated vendor/
industry representative).
Any interested parties wishing to provide written comments on any agenda items should be aware of the following relevant deadlines for
provision of written comments on the agenda to ensure comment review by all parties. Additional verbal comments on any issue can be
provided in person at the Panel meeting following a statement of conflict of interest. The applicant(s) who submitted the original code
change application is automatically considered an interested party and are notified by AMA staff of any request for review submitted by
another party.
*Interested party requests will not be processed until the interested party submits a signed confidentiality agreement and
Updated November 11, 2016
disclosure of interest form. Interested party requests will be processed within 5 days of receipt of the requested forms. Written
comments for these requests are due within 10 days upon receipt of materials. However, based upon receipt of these materials
the deadline for written comments may vary. Please follow the instructions in the correspondence provided by AMA staff.
Updated November 11, 2016
Issues
Molecular Pathology
Pathology/Laboratory
(Other than Molecular
Pathology)
Written Comment Deadlines
Comments Deadline
Tabs
(Noon, CDT)
17, 18, 19, 20, 21, 22,
December 2, 2016
23, 24, 25
26, 27, 28, 29, 30
December 16, 2016
During the time between now and the Panel meeting, the agenda will, most likely, be modified to reflect changes – additions, deletions or updates. Please check
back frequently for the most up to date information. Outcomes on these actions will be found in the CPT Editorial Panel Summary of Actions for the February
2017 meeting, which will be published on or before March 9, 2017 to the CPT home page of the AMA website http://www.ama-assn.org/go/panel-actions.
Tab #
Name
Code #
16
Drugs of Abuse-Editorial Revision
17
Tier 1 ASXL1 Leukemia
18
Tier 1 BRCA1 BRCA2-Revise 81211
81162
19
Tier 1 RUNX1 Leukemia
813XX
Add 813XX for a Molecular Pathology Tier 1 code for RUNX1 gene
analysis for acute myeloid leukemia
20
Tier 2-KAL1-ANOS1 Revision
81406
Revise the KAL1 gene test descriptor in Tier 2 code 81406 to be
consistent with the Hugo Gene Nomenclature Committee reassignment
of KAL1 to ANOS1
Updated November 11, 2016
80305, 80306, 80307
Request-Description
81X04
81211, 81162
Revise 80305, 80306, and 80307 to more accurately describe the
procedures performed
Add 81X04 for full gene sequence or targeted sequence analysis for
ASXL1
Revise code 81211 to specify analysis primarily by Sanger or capillary
sequencing methods; revise 81162 to specify analysis with sequencing
primarily by massively parallel methods
Tab #
Name
Code #
21
GSP Hereditary Breast Cancer
Disorders-Revise 81432
22
GSP Multiple Cancer Syndromes
23
GSP Panethnic Genetic Carrier
Screening Panel
81X43
Add 81X43 for panethnic genetic carrier screening panel of severe
inherited conditions
24
MAAA Kidney Transplant Rejection Risk
81X15
Add 81X15 to report gene expression profiling bt real-time quantitative
PCR of 17 genes using peripheral whole blood with an algorithm
reported as rejection risk score
25
MAAA Prostate Cancer Gene Expression
81X41
Add 81X41 for RNA expression of 46 genes, utilizing formalin-fixed
paraffin imbedded tissue with algorithm reported as a risk score
26
Albumin Urine Testing
Updated November 11, 2016
81432
Request-Description
81X56, 81X57
82042, 82043, 82044
Revise 81432 to include sequencing of at least ten genes always
including BRCA1 and BRCA2, and typically including ATM, BRIP1, CDH1,
MLH1, MSH2, MSH6, PALB2, PTEN, RAD51C, STK11, and TP53, and to
remove NBN
Add 81X56 for targeted germline hereditary cancer panel spanning
multiple cancer syndromes; add 81X57 for duplication/deletion and
large rearrangement gene panel
Revise 82042 by deleting urine as a specimen, and revising 82043, and
82044 by making microalbumin an example by adding "eg" to the
descriptors
Tab #
Name
Code #
Request-Description
27
Drug Interaction Assessment
82XXX
28
Respiratory Syncytial Virus Antigen
Detection by Nucleic Acid
876XX
29
Human Papillomavirus
87625, 87X43
Add 87X43 to report testing of high-risk HPV genotype
30
Zika Virus Detection
876XX, 867XX
Add 876XX for Zika virus detection by nucleic acid and 867XX for Zika
virus IgM antibody detection
Updated November 11, 2016
Add 82XXX for reporting drug/drug and drug/substance identification
and interaction of 120 or more drugs by definitive mass spectrometry
including assessment and risk severity score
Add 876XX for nucleic acid detection of respiratory syncytial virus, types
A and B